Harrow Health (NASDAQ:HROW) Maintains "Outperform" Rating: A Closer Look

Harrow Health, trading under the symbol HROW on the NASDAQ, is a company that has caught the attention of investors. On March 3, 2026, William Blair reiterated its "Outperform" rating for the stock, maintaining a "hold" action. At the time, the stock was trading at $38.61, as highlighted by StreetInsider. This rating reflects confidence in Harrow Health's long-term growth prospects.

The recent Q4 2025 earnings call, provided valuable insights into Harrow's financial performance. The call is a key event for investors, offering a detailed analysis of the company's achievements and challenges. It also sheds light on the company's future outlook, which is crucial for understanding potential market movements.

Despite the positive rating from William Blair, HROW has experienced a significant decrease of approximately 28%, with a drop of $14.99. The stock's price has fluctuated between a low of $38.56 and a high of $44.68 during the day. Over the past year, it has reached a high of $54.85 and a low of $20.85.

Harrow Health's market capitalization stands at approximately $1.43 billion, indicating its size and presence in the market. The trading volume of 3,933,928 shares suggests active investor interest. These figures are important for understanding the stock's liquidity and potential for future growth.